DexCom, Inc. (DXCM)
What changed in recent filings
- Institutions — 4 new · 2 added · 1 reduced13F · as of end of 2026 Q2
What changed in recent SEC filings — factual, not a buy/sell recommendation.
Institutions holding DexCom, Inc.
How many of the institutions we track reported holding this stock, quarter by quarter.
2019 Q1: 3 → 2026 Q2: 7 institutions
Counts the 52 institutions we track that reported holding this stock — their full reported holdings, not just the largest positions. Not the total number of institutional holders in the US. Figures are as of quarter-end and disclosed up to 45 days later. Descriptive only — not investment advice.
Which institutions hold DexCom, Inc.
Institutions we track that reported holding this stock in their most recent 13F.
- Baillie Gifford & Co0.90% of portfolio · held as of 2019 Q1 or earlier
- Bridgewater Associates0.11% of portfolio · since 2020 Q3
- Point72 Asset Management0.02% of portfolio · since 2025 Q3
- PRIMECAP Management0.01% of portfolio · held as of 2026 Q2 or earlier
- Caisse de depot (Quebec)0.01% of portfolio · held as of 2026 Q2 or earlier
- Blackstoneunder 0.01% of portfolio · held as of 2026 Q2 or earlier
- National Pension Service (Korea)0.03% of portfolio · held as of 2026 Q2 or earlier
Based on 13F filings — quarter-end holdings, disclosed up to 45 days later. Holding a stock is a fact we report, not a recommendation to buy or sell.
Company overview
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
What is the Biotech & Health sector?
Pharma, biotech, and medical devices. Driven by trial-result events.
DexCom, Inc. is classified under the Biotech & Health sector. See peers below.
DXCM segment revenue mix trend
Quarterly change in segment revenue share · verified from SEC filings
ETFs holding DexCom, Inc.
Per SEC N-PORT · 2026-06-30 · by weight · factual
DXCM on Stocklore
- Revenue by segment — segment weights verified from SEC filings, YoY changes, growth drivers and concentration
- Financials & earnings quality — 6 metrics (FCF conversion, ROIC, net debt, etc.) to gauge profit quality
- 13F institutional holdings — holdings and weight changes of major institutions (45-day delay)
- Sector-relative metrics — Valuation and growth compared with the Biotech & Health average
Peers · Biotech & Health
DXCM FAQ
What is DexCom, Inc. (DXCM)?
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
What sector is DexCom, Inc. in?
DexCom, Inc. is classified under Biotech & Health. Pharma, biotech, and medical devices. Driven by trial-result events.
Where can I analyze DexCom, Inc. (DXCM) stock?
On Stocklore you can see DXCM's financials & earnings quality, 13F institutional holdings, and sector-relative metrics in one place. This page is for information and tools — not a buy/sell recommendation.
Data sources: SEC EDGAR (financials & filings), 13F (institutional holdings, as of quarter-end), market data. This page is for information and analysis tools — it does not recommend buying or selling any security. Investment decisions and responsibility are your own.